Study guide
14.3 High-Risk Medications & Therapeutic Drug Monitoring
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
14.3 High-Risk Medications & Therapeutic Drug Monitoring
Key Takeaways Explain This Topic AI
Therapeutic Drug Monitoring (TDM) is indicated for narrow therapeutic index drugs where plasma concentration correlates with clinical efficacy and toxicity, measuring levels at steady state (reached after 4–5 half-lives).
Gentamicin requires pre-dose trough levels <1 mg/L to prevent irreversible vestibular/auditory ototoxicity and acute tubular necrosis; vancomycin requires trough levels of 10–15 mg/L (15–20 mg/L in severe MRSA infection) sampled before the 4th dose, with rapid infusion triggering histamine-mediated Red Man syndrome.
Digoxin toxicity (target range 0.5–2.0 mcg/L, sampled ≥6 hours post-dose) is provoked by hypokalaemia, hypomagnesaemia, renal failure, and P-glycoprotein inhibitors, manifesting with nausea, xanthopsia, and arrhythmias (ventricular ectopics, bidirectional VT); severe toxicity is treated with IV DigiFab.
Lithium toxicity (target range 0.6–0.8 mmol/L, sampled 12 hours post-evening dose) is precipitated by volume depletion, NSAIDs, ACE inhibitors, and thiazide diuretics; phenytoin follows non-linear zero-order saturation kinetics with nystagmus representing the earliest sign of toxicity.
Last updated: October 2026
High-Risk Medications & Therapeutic Drug Monitoring
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug concentrations in blood to individualize dosage regimens, ensuring optimal therapeutic efficacy while avoiding concentration-dependent toxicity. TDM is reserved for drugs that possess a narrow therapeutic index (NTI) , marked inter-individual pharmacokinetic variability, poor correlation between dose and clinical response, and established target plasma ranges.
- Principles of Therapeutic Drug Monitoring
- The Pharmacokinetic Foundation of TDM
Steady State ( C s s C_{ss} C ss ): Occurs when the rate of drug administration equals the rate of elimination. Steady-state plasma concentration is achieved after approximately 4 to 5 elimination half-lives ( t 1 / 2 t_{1/2} t 1/2 ) following initiation or dose adjustment. Sampling before steady state leads to premature, erroneous dose changes.
Trough Concentration ( C m i n C_{min} C min ): The lowest plasma drug concentration during a dosing interval, sampled immediately prior to (within 30 minutes of) the next scheduled dose. Trough levels reflect drug clearance, drug accumulation, and risk of toxicity.
Peak Concentration ( C m a x C_{max} C ma x ): The highest drug concentration achieved, sampled shortly after drug administration and distribution. Peak levels reflect bactericidal efficacy for concentration-dependent antimicrobials.
Summary of Core TDM Parameters (BNF & NICE Guidelines)
The British National Formulary (BNF) and NICE prescribing guidelines mandate specific sampling times, target therapeutic concentrations, and toxicological thresholds for narrow therapeutic index agents:
Medication BNF Target Therapeutic Range Optimal Sampling Timing Key Precipitants of Toxicity Primary Clinical Toxicities Rescue / Antidote
Gentamicin Once-daily trough: <1 mg/L (Peak: 16–24 mg/L) Trough: <30 min before 2nd/3rd dose; Peak: 1 hr post-infusion Renal impairment, dehydration, concomitant loop diuretics or vancomycin Ototoxicity (vestibular & cochlear, often permanent), Nephrotoxicity (reversible ATN) Stop drug, hydrate, therapeutic dose adjustment
Vancomycin Trough: 10–15 mg/L (15–20 mg/L in severe MRSA/endocarditis) Pre-dose trough immediately before 4th dose (at steady state) Renal impairment, concurrent aminoglycosides / pip-taz, rapid IV infusion Nephrotoxicity, ototoxicity, Red Man syndrome (non-IgE histamine release) Slow infusion (<10 mg/min), antihistamines
Digoxin BNF target: 0.5–2.0 mcg/L (optimal in HFrEF: 0.5–0.9 mcg/L) ≥6 hours post-dose (to allow myocardial distribution) Hypokalaemia , hypomagnesaemia, renal failure, amiodarone, verapamil Xanthopsia (yellow-green halos), nausea, heart block, ventricular ectopics Stop drug, correct K+, IV DigiFab (if K+ >5.5 or shock)
Lithium Maintenance: 0.6–0.8 mmol/L (Acute mania: 0.8–1.0 mmol/L) Exactly 12 hours post-evening dose (trough) Dehydration, thiazide diuretics , NSAIDs, ACE inhibitors/ARBs Coarse tremor, ataxia, dysarthria, nephrogenic diabetes insipidus, seizures 0.9% saline hydration; haemodialysis for severe toxicity (EXTRIP criteria)
Phenytoin BNF target: 10–20 mg/L (zero-order saturation kinetics) Trough immediately pre-dose at steady state Small dose increments, hepatic enzyme saturation (CYP2C9/2C19) Horizontal nystagmus (earliest sign), ataxia, confusion, gum hypertrophy Dose reduction, correct for low albumin
Theophylline BNF target: 10–20 mg/L (55–110 micromol/L) 4–6 hours post-dose or post-infusion start CYP1A2 inhibitors (ciprofloxacin, clarithromycin, erythromycin) Intractable vomiting, tachyarrhythmias, hypokalaemia, refractory seizures Multiple-dose activated charcoal, haemodialysis
- Antimicrobial TDM: Aminoglycosides & Glycopeptides
- 1. Gentamicin (Aminoglycoside)
Gentamicin exerts bactericidal activity against aerobic Gram-negative bacilli (e.g., Pseudomonas aeruginosa , Escherichia coli , Klebsiella ) by irreversibly binding the bacterial 30S ribosomal subunit to arrest protein synthesis. It displays concentration-dependent killing and a prolonged post-antibiotic effect (PAE) .
Extended-Interval Once-Daily Dosing (5–7 mg/kg IV): In modern UK hospital practice, once-daily high-dose administration is preferred over multiple-daily dosing because it maximizes peak concentration ( C m a x C_{max} C ma x /MIC ratio ≥8–10) while allowing plasma concentrations to drop to near-zero for part of the 24-hour cycle, mitigating accumulation.
Sampling Schedule & Target Thresholds:
Trough Concentration: Sampled immediately prior to (within 30 minutes of) the next scheduled dose (typically before the 2nd dose in once-daily regimens, or using the 6–14 hour single-sample Hartford Nomogram ).
Target Trough Level: Must be <1 mg/L (<2 mg/L in multi-dose divided regimens) to prevent drug accumulation.
Toxicity Profile:
Ototoxicity: Vestibular damage (vertigo, ataxia, oscillopsia) and cochlear damage (tinnitus, high-frequency sensorineural hearing loss). Damage results from progressive accumulation in endolymph and perilymph, causing apoptosis of sensory hair cells. Crucial point: Aminoglycoside ototoxicity is frequently permanent and irreversible .
Nephrotoxicity: Accumulation in proximal renal tubular epithelial cells triggers acute tubular necrosis (ATN) , characterized by non-oliguric renal impairment, rising serum creatinine, and proteinuria. Nephrotoxicity is typically reversible upon drug cessation.
2. Vancomycin (Glycopeptide)
Vancomycin is a large glycopeptide antimicrobial active exclusively against Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA), Enterococcus faecalis , and coagulase-negative staphylococci. It inhibits peptidoglycan synthesis by binding the D-alanyl-D-alanine terminus of cell wall precursors, displaying time-dependent killing (optimised by an AUC 24 / MIC ≥ 400 \text{AUC}_{24}/\text{MIC} \ge 400 AUC 24 / MIC ≥ 400 ).
Sampling Schedule & Target Trough Levels:
Administered as intermittent IV infusions; levels are measured immediately prior to the 4th dose (at steady state).
Standard Target Trough Level: 10 – 15 mg/L for mild-to-moderate Gram-positive infections.
High Target Trough Level (15 – 20 mg/L): Required for deep-seated or severe infections: MRSA bacteraemia, infective endocarditis, osteomyelitis, hospital-acquired pneumonia, and septic arthritis.
Adverse Effects & Toxicity:
Nephrotoxicity: Toxic acute tubular necrosis and interstitial nephritis, exacerbated by concomitant loop diuretics, aminoglycosides, or piperacillin-tazobactam. Monitor creatinine.
Ototoxicity: Auditory nerve damage, especially at high sustained trough levels (>20 mg/L).
Red Man Syndrome (Vancomycin Infusion Reaction): A non-immunological anaphylactoid reaction triggered by rapid intravenous infusion . Rapid administration directly stimulates mast cells and basophils to degranulate, releasing large quantities of histamine without IgE involvement. Features: Intense pruritus, erythema, and erythematous flushing over the face, neck, and upper trunk ('mantle' distribution), occasionally accompanied by hypotension and bronchospasm. Prevention & Management: Slow the IV infusion rate to a maximum of 10 mg/min (or infuse each 1 g dose over at least 100 minutes) ; pre-treatment with oral antihistamines (cetirizine or chlorphenamine).
Cardiovascular TDM: Digoxin
Digoxin is a cardiac glycoside extracted from Digitalis purpurea , indicated for rate control in permanent atrial fibrillation and as an adjunct in symptomatic heart failure with reduced ejection fraction (HFrEF).
Mechanism of Action: Selectively inhibits the myocardial cell membrane Na⁺/K⁺-ATPase pump . Intracellular sodium rises, which blunts the activity of the sodium-calcium (Na⁺/Ca²⁺) exchanger. Consequently, intracellular calcium stores in the sarcoplasmic reticulum increase, producing positive inotropy (increased myocardial contractility). Concurrently, digoxin stimulates central vagal nuclei, slowing AV node conduction and prolonging the refractory period ( negative chronotropy ).
Target Therapeutic Plasma Range: 0.5 – 2.0 mcg/L (In chronic heart failure, the optimal target is narrower: 0.5 – 0.9 mcg/L ; levels >1.2 mcg/L increase mortality without conferring added functional benefit).
Sampling Timing Rule: Blood sampling must occur at least 6 hours post-dose (or immediately prior to the next scheduled dose). Digoxin undergoes a prolonged tissue distribution phase; sampling earlier than 6 hours yields falsely elevated serum concentrations that do not reflect myocardial tissue saturation.
Precipitants of Digoxin Toxicity
Hypokalaemia (#1 Precipitant): Potassium and digoxin compete for the same binding site on the extracellular alpha-subunit of the myocardial Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase pump. Under hypokalaemic conditions (e.g. secondary to furosemide or bendroflumethiazide), decreased potassium competition allows excessive digoxin binding and severe pump inhibition even at low or normal serum digoxin concentrations.
Hypomagnesaemia & Hypercalcaemia: Low magnesium potentiates myocardial irritability; hypercalcaemia compounds intracellular calcium overload, precipitating malignant arrhythmias.
Renal Impairment: Digoxin is 70–80% eliminated unchanged by the kidneys; acute or chronic renal decline causes rapid drug accumulation.
Pharmacological Drug Interactions: Drugs that inhibit P-glycoprotein or displace digoxin from tissue binding sites (e.g. amiodarone , verapamil , diltiazem , clarithromycin , quinidine , spironolactone ) double plasma digoxin levels unless the maintenance dose is halved.
Clinical Manifestations of Digoxin Toxicity
Gastrointestinal (Earliest Symptoms): Anorexia, nausea, vomiting, abdominal pain, diarrhea.
Neurological & Visual: Confusion, delirium, headache, fatigue, and pathognomonic visual disturbances: blurred vision, photophobia, and xanthopsia (yellow-green visual haloes or altered colour perception).
Cardiovascular Arrhythmias: Can induce virtually any cardiac arrhythmia:
Ventricular bigeminy and ventricular ectopics (commonest overall arrhythmia).
Paroxysmal atrial tachycardia with variable (2:1) AV block (highly characteristic).
Bidirectional ventricular tachycardia (pathognomonic of severe digoxin cardiotoxicity).
Severe sinus bradycardia, sinoatrial arrest, and complete heart block.
Management of Digoxin Toxicity
Stop Digoxin: Cease drug administration immediately; monitor continuous cardiac rhythm.
Correct Electrolytes: Correct hypokalaemia urgently (target serum potassium 4.0–5.0 mmol/L using IV potassium chloride infusions); correct hypomagnesaemia.
Manage Bradyarrhythmias: Administer IV atropine (500 micrograms) for symptomatic bradycardia or high-grade AV block.
Definitive Antidote (DigiFab / Digibind): Administer Digoxin-specific antibody fragments (DigiFab) IV. Indications for DigiFab:
Life-threatening ventricular arrhythmias or haemodynamic instability.
Severe, refractory hyperkalaemia ( serum potassium >5.5 mmol/L in acute overdose; elevated potassium reflects massive poisoned systemic Na + / K + \text{Na}^+/\text{K}^+ Na + / K + pump failure and predicts near-100% mortality without antibody rescue).
Acute ingestion >10 mg in adults or serum digoxin concentration >10 mcg/L.
- Neuropsychiatric TDM: Lithium & Phenytoin
- 1. Lithium Carbonate
Lithium is the gold-standard mood stabilizer indicated for the acute treatment of mania and long-term prophylaxis of bipolar affective disorder. It possesses a very narrow therapeutic index and is eliminated exclusively by renal excretion via glomerular filtration.
Target Therapeutic Range:
Maintenance Prophylaxis: 0.6 – 0.8 mmol/L .
Acute Mania / Relapse: 0.8 – 1.0 mmol/L .
Sampling Protocol: Blood samples must be collected exactly 12 hours post-evening dose (typically 12 hours after the 20:00 or 22:00 dose). Levels are checked 1 week after starting and after each dose change, then weekly until stable; then every 3 months for the first year and every 6 months after that if stable (3-monthly for higher-risk groups; NICE CG185). Thyroid function tests (TFTs) and renal function tests (U&Es, eGFR) must be checked every 6 months (risk of nephrogenic diabetes insipidus, chronic tubulointerstitial nephritis, and hypothyroidism).
Precipitants of Lithium Toxicity:
Anything causing intravascular volume depletion or decreased renal sodium delivery triggers compensatory increased sodium reabsorption in the proximal convoluted tubule. Because lithium is handled by the kidney identically to sodium, lithium is co-reabsorbed, leading to toxic retention.
Culprit Precipitants: Dehydration, febrile illness, salt-restricted diet, gastroenteritis, Thiazide diuretics (highest risk; deplete distal sodium), NSAIDs (inhibit renal prostaglandins, reducing GFR), and ACE inhibitors / ARBs .
Clinical Manifestations of Toxicity:
Mild to Moderate Toxicity (1.5 – 2.0 mmol/L): Coarse tremor (distinguished from fine physiological tremor), anorexia, nausea, vomiting, diarrhea, lethargy, muscle weakness, hyperreflexia.
Severe Toxicity (>2.0 mmol/L): Gross cerebellar ataxia, dysarthria, nystagmus, myoclonus, fasciculations, acute confusion, seizures, renal failure, circulatory collapse, and coma.
Management: Stop lithium; aggressive intravenous hydration with 0.9% sodium chloride (promotes natriuresis and renal lithium clearance); monitor electrolytes and lithium levels every 4–6 hours. Discuss with TOXBASE or the National Poisons Information Service: the EXTRIP workgroup recommends haemodialysis if lithium is above 4.0 mmol/L with impaired kidney function , or if there is decreased consciousness, seizures or life-threatening dysrhythmia whatever the level.
2. Phenytoin
Phenytoin is an antiepileptic drug indicated for tonic-clonic seizures and focal seizures, and as a second-line intravenous agent in status epilepticus. It blocks voltage-gated sodium channels in neuronal membranes.
Non-Linear (Zero-Order) Saturation Kinetics: At low therapeutic doses, phenytoin clearance follows first-order kinetics (elimination proportional to concentration). However, within the therapeutic plasma range, the hepatic cytochrome P450 enzymes responsible for its metabolism ( CYP2C9 and CYP2C19 ) become completely saturated ( Michaelis-Menten kinetics ). Once saturation occurs, elimination becomes constant regardless of concentration (zero-order). Consequently, a minor percentage increase in daily dose produces a massive, exponential, unpredictable surge in plasma concentration and acute toxicity .
Target Therapeutic Range: 10 – 20 mg/L (Phenytoin is 90% bound to serum albumin; in patients with hypoalbuminaemia or renal disease, total plasma levels appear falsely low; calculate corrected phenytoin using the Sheiner-Tozer formula).
Acute Concentration-Dependent Toxicity:
>20 mg/L: Nystagmus (horizontal gaze-evoked nystagmus is the earliest and most sensitive physical sign of toxicity).
>30 mg/L: Truncal and gait ataxia, diplopia, slurred speech (dysarthria), nausea, vomiting.
>40 mg/L: Lethargy, confusion, ophthalmoplegia, coma, and paradoxical seizure aggravation.
Chronic Idiosyncratic / Cosmetic Adverse Effects: Gingival hyperplasia (gum overgrowth in up to 50%), coarsening of facial features, hirsutism, peripheral motor-sensory neuropathy, cerebellar atrophy, folate deficiency with megaloblastic anaemia, osteomalacia (accelerated vitamin D catabolism), and teratogenicity ( Fetal Hydantoin Syndrome ).
Respiratory TDM: Theophylline / Aminophylline
Theophylline (and its water-soluble ethylenediamine salt aminophylline , ratio 1:0.8) is a methylxanthine phosphodiesterase (PDE) inhibitor that promotes intracellular cyclic AMP accumulation, inducing bronchodilation and mild diaphragm inotropic stimulation in acute severe asthma and COPD exacerbations.
Target Therapeutic Range: 10 – 20 mg/L (or 55–110 micromol/L). Sampled 4–6 hours post-dose (oral) or 4–6 hours after initiating an IV infusion.
Pharmacokinetics & CYP1A2 Interactions: Theophylline is heavily metabolized by hepatic CYP1A2 . Enzyme inhibitors ( ciprofloxacin , erythromycin , clarithromycin , cimetidine ) cause rapid theophylline retention and severe toxicity.
Toxicity Manifestations: Anorexia, persistent intractable vomiting, agitation, sinus tachycardia, atrial and ventricular tachyarrhythmias, severe hypokalaemia, and refractory, life-threatening epileptic seizures (often unresponsive to standard anticonvulsants).
Management: Stop the drug; administer multiple doses of oral activated charcoal (enhances gastrointestinal clearance via gastrointestinal dialysis); manage tachyarrhythmias with beta-blockers; arrange emergency haemoperfusion or haemodialysis for severe poisoning.